V Square Quantitative Management LLC Purchases 9,807 Shares of Johnson & Johnson (NYSE:JNJ)

V Square Quantitative Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 29.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,924 shares of the company's stock after purchasing an additional 9,807 shares during the period. Johnson & Johnson makes up approximately 1.1% of V Square Quantitative Management LLC's investment portfolio, making the stock its 12th largest holding. V Square Quantitative Management LLC's holdings in Johnson & Johnson were worth $6,790,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. 4J Wealth Management LLC boosted its stake in Johnson & Johnson by 2.2% in the 4th quarter. 4J Wealth Management LLC now owns 2,835 shares of the company's stock worth $444,000 after purchasing an additional 62 shares during the period. My Personal CFO LLC increased its holdings in Johnson & Johnson by 1.4% during the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company's stock worth $713,000 after buying an additional 62 shares during the last quarter. Eagle Strategies LLC raised its holdings in shares of Johnson & Johnson by 1.8% in the 4th quarter. Eagle Strategies LLC now owns 3,589 shares of the company's stock valued at $563,000 after purchasing an additional 63 shares during the period. Clearview Wealth Advisors LLC raised its stake in Johnson & Johnson by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company's stock valued at $685,000 after buying an additional 64 shares during the period. Finally, Brookmont Capital Management boosted its position in Johnson & Johnson by 0.4% during the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company's stock worth $2,328,000 after purchasing an additional 64 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. Bank of America dropped their target price on Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, April 17th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 17th. HSBC raised Johnson & Johnson from a "hold" rating to a "buy" rating and upped their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $175.86.

Johnson & Johnson Trading Up 1.5 %

Shares of NYSE:JNJ traded up $2.28 on Wednesday, hitting $153.52. The company had a trading volume of 6,608,309 shares, compared to its average volume of 7,354,839. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a market capitalization of $369.47 billion, a price-to-earnings ratio of 9.57, a P/E/G ratio of 2.49 and a beta of 0.55. The firm's 50-day simple moving average is $151.73 and its two-hundred day simple moving average is $155.11. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion for the quarter, compared to analysts' expectations of $21.39 billion. During the same quarter in the previous year, the business posted $2.68 EPS. Johnson & Johnson's revenue was up 2.3% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.23%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson's payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.